Bladder Cancer Trial, Recruiting NCT06101277 Sponsor: University of California, Davis Condition: Bladder Cancer
Back to Bladder Cancer

Bladder Cancer Trial, Recruiting

NCT06101277
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must have one of these specific cancers, confirmed by lab testing: small bowel cancer (Cohort B), or pancreatic, ampullary, colorectal, or appendiceal cancer (Cohort C).
  • You must be at least 18 years old at the time you give your consent to join.
  • You must be willing to follow all study requirements and be available for the full duration of the study.
  • You must sign and date a consent form agreeing to take part.
  • You must currently be on a systemic treatment (such as chemotherapy) and be able to continue that same treatment, with no more than a 30-day break planned to allow for a focused local treatment to a specific area.
  • You must have already had at least one round of systemic treatment for cancer that has spread, and your most recent treatment must have kept the majority of your cancer stable for at least 3 months before new spots appeared.
  • You must have 5 or fewer spots of cancer that are growing or are newly found.
  • All of your growing or new cancer spots must be safely treatable with a focused local treatment, as decided by your radiation or interventional radiology specialist.

Who may not be able to join:

  • You may not be able to join if other health conditions make it unsafe for you to receive focused local treatments.
  • You may not be able to join if past treatment side effects have made it unsafe or not possible for you to receive focused local treatments.
  • You may not be able to join if you have cancer spots in your brain that are currently growing.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Edward Kim, MD, PhD, University of California, Davis

Phone: 916-382-6970

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
5 October 2023
Est. completion
5 December 2033

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of participants with controlled disease

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov